Forest Labs (FRX-$40.45) has demonstrated limited success in filling the earnings void created by the patent expiry for Lexapro, its erstwhile blockbuster antidepressant. Additionally, given billionaire activist Carl Icahn’s dogged criticism of past management missteps, the drug maker's days as a stand-alone company are likely numbered.
Potential bidders that could emerge are cash-rich, big pharma -- such as Lilly, Pfizer, Merck and Johnson & Johnson -- active in the same therapeutic disease spaces, and looking to complement their existing franchises with the drug maker’s portfolio of cardiovascular, respiratory, central nervous system and respiratory treatments.
Continue reading at YCharts: The Dope On a Forest Labs Takeover
No comments:
Post a Comment